The UP Study results

Preclinical data have suggested that the bile acid Ursodeoxycholic acid (or UDCA) has neuroprotective properties in models of Parkinson’s. Researchers in Sheffield have led much of this research and they have also been coordinating a clinical trial assessing this molecule in people with Parkinson’s. The study was called the “UDCA in […]

Just a lysosomal enzyme…

About 5% of individuals affected by Parkinson’s carry a genetic variation in a region of their DNA called the GBA1 gene. This area of DNA provides the instructions for making an enzyme called GCase, which is known to be involved in cellular waste disposal. Recently, however, researchers have discovered that GCase […]

Year in review: 2022

At the end of each year, it is a useful process to take stock and review what we have learnt over the last 12 months. 2022 has been an extremely busy year for Parkinson’s research, with a lot of clinical trial results and new insights. As the world continues to re-open […]

Disease modification-ish

Semantics matters – particularly regarding our communication on ideas like “disease modification” for neurodegenerative conditions. There is a big difference between “disease eradication” (zero worldwide incidence), “disease correction” (the halting/reversing of progression) and “disease modification” (improving the trajectory of disease). Recently, researchers in Japan have demonstrated “disease modification” in motor neuron […]

A rising tide with liraglutide

A class of diabetes drugs called GLP-1 receptor agonists have exhibited neuroprotective properties in models of Parkinson’s, and a Phase IIb clinical trial produced encouraging. This research has led to a number of parties to start investigating new and old GLP-1 receptor agonists for their potential to slow the progression of […]